Nurix Therapeutics Files Q1 2026 10-Q Report

Ticker: NRIX · Form: 10-Q · Filed: Apr 8, 2026 · CIK: 0001549595

Sentiment: neutral

Topics: 10-Q, quarterly-report, financials

TL;DR

Nurix Therapeutics filed its 10-Q for Feb 28, 2026. Check financials.

AI Summary

Nurix Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ending February 28, 2026. The filing includes financial statements and disclosures required for public companies. The company's mailing and business address is 1600 Sierra Point Parkway, Brisbane, CA 94005.

Why It Matters

This filing provides investors with an update on Nurix Therapeutics' financial performance and operational status for the recent quarter, crucial for investment decisions.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or unusual disclosures.

Key Numbers

Key Players & Entities

FAQ

What is the CIK number for Nurix Therapeutics, Inc.?

The CIK number for Nurix Therapeutics, Inc. is 0001549595.

When was this 10-Q filing accepted by the SEC?

This 10-Q filing was accepted on 2026-04-08.

What period does this 10-Q report cover?

This 10-Q report covers the period ending 2026-02-28.

What is the business address of Nurix Therapeutics, Inc.?

The business address of Nurix Therapeutics, Inc. is 1600 Sierra Point Parkway, Brisbane, CA 94005.

What is the SIC code listed for Nurix Therapeutics, Inc.?

The SIC code listed for Nurix Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on April 8, 2026 regarding Nurix Therapeutics, Inc. (NRIX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing